Related Experiment Video
Updated: Jun 12, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Translating Data Into Clinical Tools: An Integrative Strategy for Precision Biomarker Identification in Soft Tissue
Masoume Avateffazeli1, Rahem Rahmati1,2, Abdolreza Mohammadnia3
1Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cancer Informatics
|June 11, 2026
Summary
Researchers identified a 26-gene signature for soft tissue sarcoma (STS) patient survival and developed A1CF-based diagnostic panels for STS. These novel biomarkers require further validation for clinical use.
Area of Science:
- Oncology
- Bioinformatics
- Genomics
Background:
- Soft tissue sarcomas (STSs) are rare, heterogeneous cancers with over 70 subtypes.
- Late diagnosis due to complexity leads to poor outcomes for STS patients.
Purpose of the Study:
- Identify and validate novel transcriptomic biomarkers for STS diagnosis and prognosis.
- Utilize an integrative machine learning and bioinformatics framework for biomarker discovery.
Main Methods:
- Analyzed RNA-seq and clinical data from 261 STS samples from The Cancer Genome Atlas (TCGA).
- Implemented differential expression analysis, functional enrichment, and protein-protein interaction network construction.
- Employed machine learning for feature selection and developed diagnostic/prognostic models.
Main Results:
- Identified a 26-gene prognostic signature (15 upregulated, 11 downregulated) linked to overall survival.
- A1CF alone achieved an AUC of 0.70 for diagnosis; A1CF-ATP6V0D2 and A1CF-LECT2 combinations reached AUCs of 0.743 and 0.796.
- External validation confirmed A1CF dysregulation in STS tumor tissues.
Conclusions:
- Discovered a novel 26-gene prognostic signature and A1CF-based diagnostic panels for STS using computational methods.
- These biomarkers are exploratory candidates for STS diagnosis and prognosis.
- Experimental and prospective clinical validation are necessary before clinical application.